Tezspire, an add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma, showed significant benefits for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in a Phase 3 clinical trial.
Tezspire, an add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma, showed significant benefits for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in a Phase 3 clinical trial.
Read More
The drug achieved a 40% response rate in clinical trials for extensive-stage small cell lung cancer with progression after chemotherapy.
Read More
Amgen’s Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial, the company said on Sunday.
Read More
A greater proportion of patients with severe, uncontrolled asthma had more significant clinical responses to tezepelumab (Tezspire) than placebo, according to research presented at ATS 2022.
Read More
